Editorial

Philip Sambrook

Ther Adv Musculoskel Dis
(2009) 1(1) 3–4
DOI: 10.1177/
1759720X09345360
© The Author(s), 2009.
Reprints and permissions:
[http://www.sagepub.co.uk/
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Welcome to the first issue of *Therapeutic Advances in Musculoskeletal Disease*. This is a new medical journal covering latest advances in the medical treatment of arthropathies, osteopathies, and musculoskeletal disorders in general. We will publish every two months – I am ably assisted by Rick Adachi, Ken Saag and David Reid (Associate Editors), and a group of esteemed experts in our international editorial board. Together, our aim is to publish high-quality papers that expand our knowledge and understanding of this exciting area of medicine.

All manuscripts will be subject to peer review and, following acceptance, will be available free online within 7 weeks. We will publish leading editorials that discuss contentious issues or provide individual viewpoints on best treatments. Invited review articles will focus on therapeutic options, place in therapy, management guidance and single-drug reviews. We also welcome you to submit your unsolicited original research manuscripts. These might feature well-designed clinical results that you wish to publish rapidly – rather than wait for relatively longer publication times in some of the more established journals. We feel this will be especially welcomed by our new readers who want early access to the latest studies. Thus, the journal will provide rheumatologists, endocrinologists and musculoskeletal physicians with a much-needed additional

resource for latest drug advances in musculoskeletal disease.

Musculoskeletal disease is affecting an increasing proportion of our ageing population – the chronic diseases it includes have led to many new categories of medical treatments that are changing the way we manage patients. The drug pipeline has seen a myriad of additions and approvals for rheumatoid arthritis (e.g. tocilizumab, certolizumab, adalimumab, golimumab), osteoporosis (lasoxifene, bazedoxifene, denosumab, arzoxifene, teriparatide), gout (febuxostat, pegloticase), and osteoarthritis (diacerein), and so on. This is in addition to a healthy array of launched drugs including the bisphosphonates and biologics. While there are many journals in the area, my feeling is that we still need to have as many avenues as possible to publish and access the material. For this reason, I am enthusiastic about leading the launch of this new journal.

Therapeutic Advances in Musculoskeletal Disease is the seventh title in Sage's *Therapeutic Advances* series, following successful launches in cardiology, respiratory disease, neurology, gastroenterology, medical oncology and urology. All the titles, including this one, will be freely available on the award-winning *SAGE Journals Online* platform for the first three years – registration details may be found elsewhere in this issue. Medline and ISI applications will be made during the first year of publication

Correspondence to:
Philip Sambrook, OAM
Editor-in-Chief, Florence
and Cope Professor of
Rheumatology, University
of Sydney, Level 4,
Building 35, Royal North
Shore Hospital, St
Leonards 2065, Sydney,
NSW, Australia
[sambrook@
med.usyd.edu.au](mailto:sambrook@med.usyd.edu.au)

Visit SAGE journals online
<http://tab.sagepub.com>

SAGE JOURNALS
Online

(with retrospective indexing once accepted). The first two titles in the series, launched in late 2007, achieved Medline indexing in late 2008, and our aim will be to produce a similar high-quality publication that emulates this.

Please join me in making this new journal an essential and invigorating addition to the literature on musculoskeletal medicine. I look forward to receiving your comments and manuscripts.